Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
Catalyst Pharmaceuticals (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focusing on rare and difficult-to-treat diseases, has announced its plans to release second quarter 2024 financial results on August 7, 2024, after market close. The company will host a conference call and webcast on August 8, 2024, at 8:30 AM ET to discuss the financial results and provide a business update.
Investors can access the call via US/Canada dial-in number (877) 407-8912 or international dial-in number (201) 689-8059. The webcast will be available under the Investors section on Catalyst's website, with a replay accessible for at least 30 days following the event.
Catalyst Pharmaceuticals (Nasdaq: CPRX), un'azienda biofarmaceutica in fase commerciale che si concentra su malattie rare e difficili da trattare, ha annunciato i suoi piani per rilasciare i risultati finanziari del secondo trimestre 2024 il 7 agosto 2024, dopo la chiusura del mercato. L'azienda ospiterà una conference call e webcast l'8 agosto 2024, alle 8:30 AM ET, per discutere i risultati finanziari e fornire un aggiornamento sull'attività.
Gli investitori possono accedere alla chiamata tramite il numero di accesso per US/Canada (877) 407-8912 o il numero di accesso internazionale (201) 689-8059. Il webcast sarà disponibile nella sezione Investitori del sito web di Catalyst, con una registrazione accessibile per almeno 30 giorni dopo l'evento.
Catalyst Pharmaceuticals (Nasdaq: CPRX), una empresa biofarmacéutica en etapa comercial que se enfoca en enfermedades raras y difíciles de tratar, ha anunciado sus planes de publicar los resultados financieros del segundo trimestre de 2024 el 7 de agosto de 2024, después del cierre del mercado. La empresa organizará una conferencia telefónica y webcast el 8 de agosto de 2024, a las 8:30 AM ET, para discutir los resultados financieros y proporcionar una actualización comercial.
Los inversores pueden acceder a la llamada a través del número de marcado para EE. UU./Canadá (877) 407-8912 o el número de marcado internacional (201) 689-8059. El webcast estará disponible en la sección de Inversores del sitio web de Catalyst, con una reproducción accesible durante al menos 30 días después del evento.
Catalyst Pharmaceuticals (Nasdaq: CPRX)는 희귀하고 치료하기 어려운 질병에 중점을 둔 상업 단계의 생물의약품 회사로, 2024년 8월 7일 시장 종료 후 2024년 2분기 재무 결과를 발표할 계획을 발표했습니다. 이 회사는 2024년 8월 8일 오전 8시 30분 ET에 재무 결과를 논의하고 사업 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 진행할 것입니다.
투자자는 미국/캐나다 전화 번호 (877) 407-8912 또는 국제 전화 번호 (201) 689-8059를 통해 전화를 이용할 수 있습니다. 웹캐스트는 Catalyst 웹사이트의 투자자 섹션에서 이용할 수 있으며, 이벤트 이후 최소 30일 동안 다시 볼 수 있습니다.
Catalyst Pharmaceuticals (Nasdaq: CPRX), une société bio-pharmaceutique en phase commerciale qui se concentre sur les maladies rares et difficiles à traiter, a annoncé ses plans de publier les résultats financiers du deuxième trimestre 2024 le 7 août 2024, après la clôture du marché. La société organisera un appel et un webinaire le 8 août 2024, à 8h30 HE, pour discuter des résultats financiers et fournir une mise à jour de l'activité.
Les investisseurs peuvent accéder à l'appel via le numéro d'accès US/Canada (877) 407-8912 ou le numéro d'accès international (201) 689-8059. Le webinaire sera disponible dans la section Investisseurs du site web de Catalyst, avec un replay accessible pendant au moins 30 jours après l'événement.
Catalyst Pharmaceuticals (Nasdaq: CPRX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene und schwer behandelbare Krankheiten konzentriert, hat seine Pläne bekannt gegeben, die finanziellen Ergebnisse des zweiten Quartals 2024 am 7. August 2024 nach Marktschluss zu veröffentlichen. Das Unternehmen wird am 8. August 2024 um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen Ergebnisse zu besprechen und ein Update zum Geschäft zu geben.
Investoren können über die US-/Kanada-Teilnehmernummer (877) 407-8912 oder die internationale Teilnehmernummer (201) 689-8059 auf den Anruf zugreifen. Der Webcast wird im Bereich für Investoren auf der Webseite von Catalyst verfügbar sein, mit einer Wiedergabe, die mindestens 30 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2024 financial results after the market close on Wednesday, August 7, 2024.
Catalyst's management team will host a conference call and webcast on Thursday, August 8, 2024, at 8:30 AM ET to discuss the Company's financial results and provide a business update.
Conference Call & Webcast Details
| Date: Time: US/Canada Dial-in Number: International Dial-in Number: | August 8, 2024 8:30 AM ET (877) 407-8912 (201) 689-8059 |
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on the Catalyst website for at least 30 days following the date of the event.
About Catalyst Pharmaceuticals, Inc.
With exceptional patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare and difficult-to-treat diseases. Catalyst's flagship U.S. commercial product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") in adults and pediatric patients 6 years of age and older. In January 2023, Catalyst acquired the U.S. commercial rights to FYCOMPA® (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. On July 18, 2023, Catalyst acquired an exclusive license for North America for AGAMREE® (vamorolone) oral suspension 40 mg/mL, a novel corticosteroid treatment for Duchenne Muscular Dystrophy. AGAMREE previously received FDA Orphan Drug and Fast Track designations and was approved by the FDA for commercialization in the U.S. on October 26, 2023. AGAMREE became commercially available by prescription in the U.S. on March 13, 2024.
For more information about Catalyst Pharmaceuticals, Inc., please visit the Company's website at www.catalystpharma.com. For Full Prescribing and Safety Information for FIRDAPSE®, please visit www.firdapse.com. For Full Prescribing Information, including Boxed WARNING for FYCOMPA®, please visit www.fycompa.com. For Full Prescribing Information for AGAMREE®, please visit www.agamree.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When will Catalyst Pharmaceuticals (CPRX) release its Q2 2024 financial results?
What is the date and time of Catalyst Pharmaceuticals' (CPRX) Q2 2024 earnings call?
How can investors access Catalyst Pharmaceuticals' (CPRX) Q2 2024 earnings call?
Where can I find the webcast for Catalyst Pharmaceuticals' (CPRX) Q2 2024 earnings call?
